Aquinox Pharmaceuticals ROA 2013-2018 | AQXP

Current and historical return on assets (ROA) values for Aquinox Pharmaceuticals (AQXP) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Aquinox Pharmaceuticals ROA for the three months ending December 31, 2018 was -34.57%.
Aquinox Pharmaceuticals ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-12-31 $-0.03B $0.08B -34.97%
2018-09-30 $-0.04B $0.09B -43.22%
2018-06-30 $-0.04B $0.10B -37.04%
2018-03-31 $-0.06B $0.10B -49.46%
2017-12-31 $-0.05B $0.11B -39.37%
2017-09-30 $-0.05B $0.12B -32.61%
2017-06-30 $-0.04B $0.13B -27.61%
2017-03-31 $-0.04B $0.14B -27.05%
2016-12-31 $-0.04B $0.15B -28.08%
2016-09-30 $-0.03B $0.16B -26.34%
2016-06-30 $-0.03B $0.10B -26.36%
2016-03-31 $-0.02B $0.11B -24.93%
2015-12-31 $-0.02B $0.11B -29.73%
2015-09-30 $-0.02B $0.12B -42.86%
2015-06-30 $-0.03B $0.03B -64.52%
2015-03-31 $-0.03B $0.04B -56.18%
2014-12-31 $-0.02B $0.04B -46.23%
2014-09-30 $-0.02B $0.05B -43.68%
2014-06-30 $-0.02B $0.05B -57.60%
2014-03-31 $-0.02B $0.06B -83.33%
2013-12-31 $-0.01B $0.02B -350.00%
2013-09-30 $-0.01B $0.00B -2000.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.064B $0.025B
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $49.659B 8.94
Teva Pharmaceutical Industries (TEVA) Israel $16.606B 5.73
Mylan (MYL) United Kingdom $14.803B 6.26
Bausch Health Cos (BHC) Canada $8.636B 6.14
Dr Reddy's Laboratories (RDY) India $6.502B 25.93
Supernus Pharmaceuticals (SUPN) United States $1.866B 17.31
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.845B 3.00
Homology Medicines (FIXX) United States $0.967B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.943B 87.65
CymaBay Therapeutics (CBAY) United States $0.709B 0.00
Voyager Therapeutics (VYGR) United States $0.586B 0.00
Assembly Biosciences (ASMB) United States $0.465B 0.00
Akorn (AKRX) United States $0.440B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.366B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.210B 0.00
Sol-Gel Technologies (SLGL) Israel $0.127B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.122B 0.00
Acasti Pharma (ACST) Canada $0.082B 0.00
Agile Therapeutics (AGRX) United States $0.064B 0.00
Teligent (TLGT) United States $0.062B 0.00
Evoke Pharma (EVOK) United States $0.025B 0.00
Aevi Genomic Medicine (GNMX) United States $0.014B 0.00